Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
78.47
+1.90 (2.47%)
Nov 18, 2026, 12:51 PM EST - Market open
Disc Medicine Employees
Disc Medicine had 173 employees as of September 30, 2026. The number of employees increased by 31 or 21.83% compared to the same quarter last year. That makes Disc Medicine the 27,837th largest employer in the world and 3,500th in the United States.
Employees
173
Change (1Y)
31
Growth (1Y)
21.83%
Revenue / Employee
n/a
Profits / Employee
-$1,405,214
Market Cap
3.57B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2026 | 173 | 31 | 21.83% | 173 | 0 |
| Jun 30, 2026 | 165 | 40 | 32.00% | 165 | 0 |
| Mar 31, 2026 | 154 | 60 | 63.83% | 154 | 0 |
| Dec 31, 2025 | 155 | 71 | 84.52% | 155 | 0 |
| Sep 30, 2025 | 142 | 60 | 73.17% | 142 | 0 |
| Jun 30, 2025 | 125 | 47 | 60.26% | 125 | 0 |
| Mar 31, 2025 | 94 | 16 | 20.51% | 94 | 0 |
| Dec 31, 2024 | 84 | 10 | 13.51% | 84 | 0 |
| Sep 30, 2024 | 82 | 22 | 36.67% | 82 | 0 |
| Jun 30, 2024 | 78 | 23 | 41.82% | 78 | 0 |
| Mar 31, 2024 | 78 | 27 | 52.94% | 78 | 0 |
| Dec 31, 2023 | 74 | 28 | 60.87% | 74 | 0 |
| Sep 30, 2023 | 60 | 22 | 57.89% | 60 | 0 |
| Jun 30, 2023 | 55 | 17 | 44.74% | 55 | 0 |
| Mar 31, 2023 | 51 | 13 | 34.21% | 51 | 0 |
| Dec 31, 2022 | 46 | - | - | 46 | 0 |
| Jun 30, 2022 | 38 | - | - | 37 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| AbCellera Biologics | 562 |
| Xenon Pharmaceuticals | 370 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Viridian Therapeutics | 252 |
| Relay Therapeutics | 218 |
| Parabilis Medicines | 145 |
IRON News
- 4 hours ago - Disc Medicine price target raised to $104 from $92 at Morgan Stanley - TheFly
- 6 hours ago - Disc Medicine Transcript: Jefferies Global Healthcare Conference - Transcripts
- 1 day ago - Disc Medicine Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 9 days ago - Disc Medicine Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - Disc Medicine initiated with a Buy at Guggenheim - TheFly
- 12 days ago - Disc Medicine price target raised to $127 from $120 at H.C. Wainwright - TheFly
- 13 days ago - Disc Medicine reports Q3 EPS ($1.53), consensus ($1.71) - TheFly
- 13 days ago - Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire